Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cediranib + Fulvestrant
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
The combination of cediranib and fulvestrant is a therapeutic approach that has been studied for hormone-sensitive metastatic breast cancer. This combination pairs cediranib, a highly potent vascular endothelial growth factor (VEGF) signaling inhibitor that targets all three VEGF receptors, with fulvestrant (brand name Faslodex), an estrogen receptor antagonist with no known agonist effects that competitively binds, blocks, and degrades the estrogen receptor. This combination was investigated to potentially overcome resistance mechanisms in hormone receptor-positive breast cancer. Fulvestrant itself is approved for hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy.
- Brand names
- Faslodex
- Other names
- cediranibfulvestrant
02
Targets
VEGFR3 (Vascular endothelial growth factor receptor 3)PDGFRB (Platelet-derived growth factor receptor beta)KIT (c-KIT proto-oncogene receptor tyrosine kinase)ESR1 (ERα)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)ESR2 (ERβ)
Beyond the preview
Go deeper on Cediranib + Fulvestrant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cediranib + Fulvestrant.